Biomet — Imperial Capital (February 2010)
41 slides from Biomet's conference presentation, Feb 23, 2010
Slide 1: Imperial Capital
IMPERIAL CAPITAL FEBRUARY 23, 2010 DANIEL P. FLORIN SENIOR VICE PRESIDENT & CFO BIOMET, INC.
Slide 2: Forward-Looking & Non-GAAP Financial Measures
Biologics Bracing Microfixation Orthopaedics Osteobiologics Spine Sports Medicine Trauma 3i Forward-Looking & Non-GAAP Financial Measures Forward-Looking Statements This presentation may contain forward-looking statements. They will be based upon management's current expectations and will involve ce
Slide 3: Summary Business Overview
Summary Business Overview 7,000+ team members 3,000+ sales representatives 900+ new products introduced FY 2000 – 2009 Operations in 50+ locations Products distributed in ~90 countries Eight strategic business units Company Profile Asia-Pac/ROW 11% United States 61% Europe 28% FY 2009 Revenues by Pr
Slide 4: Orthopedic market segment sizes
Orthopedic Reconstructive Devices $6,875 Dental Reconstructive Implants $740 Softgoods & Bracing $1,120 Sports Medicine $1,370 Bone Cements & Accessories $330 Spinal Products $6,865 O.R. Supplies $395 Fixation $3,395 Powered Surgical Equipment $245
Slide 5: Global orthopedic market rankings
#1 J & J/DePuy #2 Stryker/Howmedica #3 Zimmer/Centerpulse #4 Biomet #5 Synthes/Stratec #6 Smith & Nephew #4 Biomet
Slide 6: Reconstructive market by joint
Hips $2,620 Knees $3,890 Other $110 Shoulders $255
Slide 7: Demographics
Demographics 55- to 75-Year-Old U.S. Population Expected to Grow > 32% in 10 Years* Expansion of Target Population New Technologies to Treat Younger Patients Greater Activity Level & Improved Health of Elderly 54.8 Million 72.4 Million 2019 2009 *U.S. Census Bureau Projections
Slide 8: Sales Growth by Product Segment at Constant Currency
H1 FY ’10 Growth FY 2009 Growth FY 2008 Growth Recon Ex-Dental 8% 13% 12% 9% Dental 12% 13% (6%) (7%) Recon 9% 13% 9% 7% Fixation (11%) 0% 4% (1%) Spine (8%) 0% 7% 11% Other (1%) 6% 7% 8% Total 3% 10% 8% 6% Growth has rebounded from FY’07 levels, driven by core orthopedics business off-setting denta
Slide 9: U.S. Orthopaedics Performance vs. Market
Biologics Bracing Microfixation Orthopaedics Osteobiologics Spine Sports Medicine Trauma 3i Fended off significant competitive threat and re-established sales momentum U.S. Hip/Knee Growth Rates by Calendar Quarter* BIOMET 4.9% 7.5% 12.2% 12.1% 17.1% 9.0% 15.3% 11.3% 10.9% 10.4% 7.1% 9.5% MARKET 10.
Slide 10: Biomet Europe Performance vs. Market
Biologics Bracing Microfixation Orthopaedics Osteobiologics Spine Sports Medicine Trauma 3i Biomet Europe has grown substantially ahead of the market in 2008 and 2009 EU Market Share Positions CY 2007 vs. H1 CY 2009 Biomet Europe Performance vs. Market Data based on Company estimates 0.0% 2.0% 4.0%
Slide 11: International Sales at Constant Currency Growth Rates
Biologics Bracing Microfixation Orthopaedics Osteobiologics Spine Sports Medicine Trauma 3i $- $50.0 $100.0 $150.0 $200.0 $250.0 $300.0 $137.1 $156.4 Primarily includes Canada, South America, Mexico and the Pacific Rim $- $50.0 $100.0 $150.0 $200.0 $250.0 $300.0 $205.0 $241.2 264.5 International Sal
Slide 12: Reconstructive sales growth Q2'10
Recon Sales Increased 6% Worldwide (C.C.) during Q2’10 Sales Increased 9% in the U.S.
Slide 13: Hips: sales growth and new products
Sales Grew 4% WW (C.C.) during Q2’10 Sales Increased 7% in the U.S. New Product Introductions E1 Antioxidant Infused Technology Plus Liners Echo Bi-Metric PPS Primary Stem Magnum Tri-Spike Acetabular Components Biologics Bracing Microfixation Orthopaedics Osteobiologics Spine Sports Medicine Trauma
Slide 14: Hips: Key Products
Biologics Bracing Microfixation Orthopaedics Osteobiologics Spine Sports Medicine Trauma 3i Hips Key Products M ² a-Magnum Acetabular System Taperloc Hip Stem E1 Antioxidant Infused Acetabular Bearings Exceed ABT ( A dvanced Bearing Technologies) Acetabular System* B T Hips *Not Available in U.S.
Slide 15: Knees: sales growth and new products
#4 U.S. Market Position Sales Grew 12% WW (C.C.) during Q2’10 Sales Increased 11% in the U.S. New Product Introductions E1 Antioxidant Infused Tibial Bearings Regenerex Press-Fit Tibia
Slide 16: Knees: Key Products
Key Products Vanguard Complete Knee System Oxford Partial Knee System
Slide 17: Designed to Address the Entire Population
Designed to Address the Entire Population 10 Femoral and 9 Tibial Sizes, completely interchangeable No Need to “ Correct ” Our Sizing for the Female Population No Peer-Reviewed Studies Associating Failure with Gender Biomet Knees = 98% Survivorship at 15 Years (Mensch, JS, Knee Morphology as a Guide
Slide 18: Oxford Partial Knee long-term clinical results
Only Free Floating Meniscal Bearing Partial Knee Approved in U.S. Excellent Long-Term Clinical Results 98% Success Rate at 10 Years 95% Success at 15 Years 92% Success at 20 Years
Slide 19: Extremities: sales growth and key products
Sales Grew 27% WW (C.C.) during Q2’10 Sales Increased 44% in the U.S. Key Products Comprehensive Primary and Reverse Shoulders Copeland Humeral Resurfacing Head T.E.S.S. (Total Evolutive Shoulder System)* *Not Available in U.S.
Slide 20: Bone Cement: Key Products
Key Products Cobalt G HV Bone Cement StageOne Cement Hip Spacer Molds StageOne Cement Knee Spacer Molds
Slide 21: Osteobiologics: New Product Introductions
New Product Introductions Bone Graft Convenience Kit Clotalyst System Coaxial Sprayer
Slide 22: Dental sales: United States and International
United States $740 International $2,060
Slide 23: Biomet 3i: Industry Headwinds
Biologics Bracing Microfixation Orthopaedics Osteobiologics Spine Sports Medicine Trauma 3i (15%) (10%) (5%) 0% 5% 10% 15% 20% 25% CY 03 CY 04 CY 05 CY 06 CY 07 CY 08 CY 09E DENTAL IMPLANT MARKET (Constant Currency Sales Growth) QUARTERLY SALES GROWTH Constant-Currency, Based on Calendar Quarters (w
Slide 24: Biomet 3i's New Introductions
Biomet 3i’s New Introductions Encode Complete Zirconia Abutment Low Profile Conical Abutments The DU1000 Surgical Drill System ZiReal Art Ceramic Abutment
Slide 25: Strategic Priority: Turn Around U.S. Trauma and Spine
Biologics Bracing Microfixation Orthopaedics Osteobiologics Spine Sports Medicine Trauma 3i 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q Transaction Announced Transaction Closed Overhauled management team Fixed systems issues Created focused sales forces around spine and trauma
Slide 26: U.S. Spine and Fixation Sales Growth Trends
Stabilization and return to growth has been led by spine, but trauma turnaround lags; Fixation rates reflect above market craniomaxillofacial growth, more than offset by trauma, which is expected to show growth in fiscal 2011 By Fiscal Year, FY07-FY09 and Fiscal Quarter, Q1’10 – Q2’10 U.S. Spine and
Slide 27: Fixation product categories
Internal Fixation $2,110 Craniomaxillofacial Fixation $275 Electrical Stimulation $300 External Fixation $365 Growth Factors & Bone Substitute Materials $345
Slide 28: Electrical stimulation technologies
PEMF, DC, & CC Technologies FDA Acknowledged Mechanism of Action Involving Cascade of BMPs
Slide 29: Fixation: Key Products
Key Products OptiLock Proximal Humeral Plating System Phoenix Ankle Arthrodesis Nail Advanced Vision Foot Ring System
Slide 30: Fixation: New Product Introductions
New Product Introductions Custom TMJ Innovative Screw Delivery Device Neuro NexGen Next Gen Sternalock OnPoint 1.2mm Scope System Xpander (TMJ Jaw Motion Rehab System)
Slide 31: Spine product categories
Machined Allograft $520 Growth Factors & Bone Substitutes $1,075 Intervertebral Spacers $755 Electrical Stimulation $330 Motion Preservation $590 Plates, Rods, Screws $3,095 Vertebroplasty $500
Slide 32: Spine: sales growth and new products
Sales Grew 6% WW (C.C.) during Q2’10 Sales Increased 7% in the U.S. New Product Introductions Polaris Deformity Direct Vertebral Column Derotation System C-Tek MaxAn Cervical Plate System* *The C-Tek MaxAn Cervical Plate System incorporates technology developed by Gary K. Michelson, M.D.
Slide 33: Sports Medicine: Procedure-Specific Arthroscopy Products
Procedure-Specific Arthroscopy Products New Product Introductions ALLthread Knotless Suture Anchor ComposiTCP Interference Screw MicroMax FLEX Suture Anchor ZipTight Fixation System Sports Medicine Biologics Bracing Microfixation Orthopaedics Osteobiologics Spine Sports Medicine Trauma 3i Sports Med
Slide 34: Softgoods & Bracing: New Product Introductions
#4 U.S. Market Position New Product Introductions Active Ankle CF Pro Aspen Contour LSO ( L umbar- S acral- O rthosis) Aspen Contour TLSO ( T horacic- L umbar- S acral O rthosis) Aspen QuickDraw RAP ( R igid A nterior P anel) Aspen TX Collar Aspen Vista Collar Biomet Cool Sport P.A.S.S. Performance
Slide 35: Financial Highlights
FINANCIAL HIGHLIGHTS
Slide 36: Fiscal 2007–2009 Adjusted Operating Results
Adjusted Net Income and Adjusted EBITDA reflect add-backs to GAAP results for non-cash amortization and stock comp expense, sponsor fees and other special charges Fiscal 2007 – 2009 Adjusted Operating Results Biologics Bracing Microfixation Orthopaedics Osteobiologics Spine Sports Medicine Trauma 3i
Slide 37: H1 Fiscal 2010 vs. H1 Fiscal 2009 Adjusted Operating Results
Adjusted Net Income and Adjusted EBITDA reflect add-backs to GAAP results for non-cash amortization and stock comp expense, sponsor fees and other special charges H1 Fiscal 2010 vs. H1 Fiscal 2009 Adjusted Operating Results Biologics Bracing Microfixation Orthopaedics Osteobiologics Spine Sports Med
Slide 38: Balance Sheet & Cash Flow Data
Biologics Bracing Microfixation Orthopaedics Osteobiologics Spine Sports Medicine Trauma 3i CAPITAL EXPENDITURES RECEIVABLE DAYS (1) INVENTORY TURNOVER, ADJUSTED (2) 88 91 76 71 73 0 20 40 60 80 100 FY 2006 FY 2007 FY 2008 FY 2009 11/30/2009 1.15 1.14 1.30 1.34 1.37 0 0.5 1 1.5 FY 2006 FY 2007 FY 20
Slide 39: Operating Cash Flow Reconciled to Free Cash Flow
In Millions, Unaudited GAAP Operating Cash Flow Reconciled to Free Cash Flow (FCF) & Unlevered FCF H1 Fiscal 2010 vs. H1 Fiscal 2009 Six Months Ended Six Months Ended November 30, 2009 November 30, 2008 Change Cash From Operations 81.1 $ 47.6 $ Capital expenditures (106.0) (92.9) Free Cash Flow (24.
Slide 40: Flexible capital structure with significant liquidity
Total Liquidity LTM EBITDA 7.7x 6.1x At Transaction Close Today LIQUIDITY NET DEBT LEVERAGE RATIOS (including projected run rate cost savings) Flexible capital structure with significant liquidity (1) As of November 30, 2009, as defined by our Credit Agreement (2) As defined by our Credit Agreement,
Slide 41: Biomet Long-Term Track Record
CONSOLIDATED SALES ($ in Millions) Extraordinary long-term track record of revenue and profitability growth through multiple industry and macro-economic cycles 10 Year CAGR 20 Year CAGR 11.7% 15.7% Biomet Long-Term Track Record SALES $0 $500 $1,000 $1,500 $2,000 $2,500 1987 1988 1989 1990 1991 1992